Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine. Semaglutide, which is traditionally a treatment for type 2 diabetes, was given to participants who had been diagnosed with a life-threatening form of liver disease called metabolic dysfunction associated … Read more
While the use of Glucagon-like peptide-1 (GLP-1) receptor agonists for treating Type 2 diabetes is well established, strong evidence also supports use of these medications for weight loss. Employer-based health insurance coverage for these prescription drugs currently lags behind this evidence: only one fourth of large employers offer coverage of GLP-1s for weight loss to … Read more
Company says that if the application is approved, Wegovy would become the first oral formulation of a GLP-1 drug for chronic weight management Novo NordiskNOVO.B2.62%increase; green up pointing triangle said the Food and Drug Administration accepted its submission of a new drug application for a …
On Friday, the company’s health services unit Evernorth unveiled new programs in a reliable growth area: helping payers manage GLP-1 utilization. Cigna also posted first quarter results well above analyst forecasts.
Although glucagon-like peptide-1 (GLP-1) receptor agonists are primarily intended for managing type 2 diabetes (T2D) and obesity, research continues to uncover additional benefits. The latest exploration suggests that GLP-1 medications may help lower dementia risk.
For patients with type 2 diabetes (T2D) who haven’t adequately controlled their blood glucose, taking the glucagon-like peptide-1 (GLP-1) receptor agonist dulaglutide may benefit from switching to GLP-1 tirzepatide rather than upping their dosage.
CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare Pharmacy to provide direct-to-patient doses of Wegovy for $499 per month. Eligible self-paying patients can also get the $499-per-month price at their local pharmacy. The new formulary change … Read more
